Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Nanotechnology approaches for personalized treatment of multidrug resistant cancers.

Minko T, Rodriguez-Rodriguez L, Pozharov V.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1880-95. doi: 10.1016/j.addr.2013.09.017. Epub 2013 Oct 10. Review.

2.

Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.

Bar-Zeev M, Livney YD, Assaraf YG.

Drug Resist Updat. 2017 Mar;31:15-30. doi: 10.1016/j.drup.2017.05.002. Epub 2017 May 21. Review.

PMID:
28867241
3.

Role of integrated cancer nanomedicine in overcoming drug resistance.

Iyer AK, Singh A, Ganta S, Amiji MM.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21. Review.

PMID:
23880506
4.

Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Milane L, Ganesh S, Shah S, Duan ZF, Amiji M.

J Control Release. 2011 Oct 30;155(2):237-47. doi: 10.1016/j.jconrel.2011.03.032. Epub 2011 Apr 8. Review.

5.

Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.

Xue X, Liang XJ.

Chin J Cancer. 2012 Feb;31(2):100-9. doi: 10.5732/cjc.011.10326. Epub 2012 Jan 9. Review.

6.

Recent progress in nanotechnology for cancer therapy.

Tang MF, Lei L, Guo SR, Huang WL.

Chin J Cancer. 2010 Sep;29(9):775-80. Review.

7.

Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Kirtane AR, Kalscheuer SM, Panyam J.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1731-47. doi: 10.1016/j.addr.2013.09.001. Epub 2013 Sep 10. Review.

8.

Carbon nanotubes for delivery of small molecule drugs.

Wong BS, Yoong SL, Jagusiak A, Panczyk T, Ho HK, Ang WH, Pastorin G.

Adv Drug Deliv Rev. 2013 Dec;65(15):1964-2015. doi: 10.1016/j.addr.2013.08.005. Epub 2013 Aug 14. Review.

PMID:
23954402
9.

Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T.

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7. Epub 2005 Aug 25.

10.

In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.

Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T.

J Control Release. 2006 Aug 28;114(2):153-62. Epub 2006 Jun 15.

PMID:
16889867
11.

Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.

Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T.

J Control Release. 2013 Nov 10;171(3):349-57. doi: 10.1016/j.jconrel.2013.04.018. Epub 2013 May 3.

12.

Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.

Taratula O, Garbuzenko OB, Chen AM, Minko T.

J Drug Target. 2011 Dec;19(10):900-14. doi: 10.3109/1061186X.2011.622404. Epub 2011 Oct 10.

PMID:
21981718
13.

Nanoparticle therapeutics: Technologies and methods for overcoming cancer.

Cerqueira BB, Lasham A, Shelling AN, Al-Kassas R.

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):140-51. doi: 10.1016/j.ejpb.2015.10.007. Epub 2015 Oct 26. Review.

PMID:
26515260
14.

Nanomedicine to overcome cancer multidrug resistance.

Yang X, Yi C, Luo N, Gong C.

Curr Drug Metab. 2014;15(6):632-49. Review.

PMID:
25255871
15.

Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.

Kibria G, Hatakeyama H, Harashima H.

Arch Pharm Res. 2014 Jan;37(1):4-15. doi: 10.1007/s12272-013-0276-2. Epub 2013 Nov 23. Review.

PMID:
24272889
16.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Pérez-Herrero E, Fernández-Medarde A.

Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Review.

17.

Circumventing tumor resistance to chemotherapy by nanotechnology.

Liang XJ, Chen C, Zhao Y, Wang PC.

Methods Mol Biol. 2010;596:467-88. doi: 10.1007/978-1-60761-416-6_21.

18.

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

Shapira A, Livney YD, Broxterman HJ, Assaraf YG.

Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Review.

PMID:
21330184
19.

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Gandhi NS, Tekade RK, Chougule MB.

J Control Release. 2014 Nov 28;194:238-56. doi: 10.1016/j.jconrel.2014.09.001. Epub 2014 Sep 7. Review.

20.

Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.

Yin Q, Shen J, Zhang Z, Yu H, Li Y.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1699-715. doi: 10.1016/j.addr.2013.04.011. Epub 2013 Apr 20. Review.

PMID:
23611952

Supplemental Content

Support Center